This whitepaper discusses ways of modeling biomanufacturing networks that explicitly account for supply chain risks. Capturing the likelihood and effect of risks is a critical first step in determining how much inventory is needed to buffer against adverse events, therefore the level of safety stocks that are required. In some cases, supply chain resilience and flexibility are not mutually exclusive, and with careful planning, a network can be constructed that optimizes both. 

Click here to read whitepaper.

Rx-360, an international pharmaceutical and biotech industry supply chain consortium, has set up a program of joint audits. The goal of this project is to expand audit coverage and reduce duplicated audit efforts. SAFC recently took part in a pilot audit program.